MX2020005785A - Formulaciones inyectables de toxina botulínica y métodos de uso de las mismas que tienen una alta tasa de respuesta y una larga duración del efecto. - Google Patents
Formulaciones inyectables de toxina botulínica y métodos de uso de las mismas que tienen una alta tasa de respuesta y una larga duración del efecto.Info
- Publication number
- MX2020005785A MX2020005785A MX2020005785A MX2020005785A MX2020005785A MX 2020005785 A MX2020005785 A MX 2020005785A MX 2020005785 A MX2020005785 A MX 2020005785A MX 2020005785 A MX2020005785 A MX 2020005785A MX 2020005785 A MX2020005785 A MX 2020005785A
- Authority
- MX
- Mexico
- Prior art keywords
- botulinum toxin
- duration
- methods
- response rate
- toxin formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
Abstract
Esta invención proporciona composiciones inyectables que comprenden toxina botulínica que pueden administrarse a un sujeto para diversos fines terapéuticos, estéticos y/o cosméticos. Las composiciones inyectables incluidas en la invención exhiben una o más ventajas sobre las formulaciones convencionales de toxina botulínica, que incluyen una antigenicidad reducida, una tendencia reducida a experimentar difusión localizada no deseada después de la inyección, una mayor duración de la eficacia clínica o una potencia mejorada, tasas de respondedores más altas, inicio más rápido de la eficacia clínica y/o estabilidad mejorada. De acuerdo con la invención, el tratamiento único de las composiciones por inyección proporciona respuestas clínicas significativas y al menos una duración de efecto de 26 semanas en un sujeto sometido a tratamiento, tal como se proporciona mediante los métodos de tratamiento descritos, así como tasas de respuesta y/o una duración del efecto más larga después de tratamientos subsecuentes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762594529P | 2017-12-04 | 2017-12-04 | |
US201862774850P | 2018-12-03 | 2018-12-03 | |
PCT/US2018/063942 WO2019113133A1 (en) | 2017-12-04 | 2018-12-04 | Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020005785A true MX2020005785A (es) | 2020-10-28 |
Family
ID=66750627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020005785A MX2020005785A (es) | 2017-12-04 | 2018-12-04 | Formulaciones inyectables de toxina botulínica y métodos de uso de las mismas que tienen una alta tasa de respuesta y una larga duración del efecto. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20200384090A1 (es) |
EP (1) | EP3720475A4 (es) |
JP (1) | JP2021505570A (es) |
KR (1) | KR20200105829A (es) |
CN (1) | CN111655279A (es) |
AU (1) | AU2018378465A1 (es) |
BR (1) | BR112020011098A2 (es) |
CA (1) | CA3084175A1 (es) |
CO (1) | CO2020008231A2 (es) |
IL (1) | IL275032A (es) |
MX (1) | MX2020005785A (es) |
PH (1) | PH12020550821A1 (es) |
RU (1) | RU2020121540A (es) |
SG (1) | SG11202005239YA (es) |
WO (1) | WO2019113133A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI1015938A2 (pt) | 2009-06-25 | 2016-09-27 | Revance Therapeutics Inc | formulações da toxina botulínica livre de albumina |
EP3624819A4 (en) * | 2017-05-18 | 2021-03-24 | Revance Therapeutics, Inc. | METHOD OF TREATMENT OF CERVICAL DYSTONIA |
BR112022023413A2 (pt) * | 2020-06-05 | 2022-12-20 | Merz Pharma Gmbh & Co Kgaa | Tratamento de rugas faciais com toxina botulínica de alta dose e baixo volume |
CA3195483A1 (en) * | 2020-10-13 | 2022-04-21 | Revance Therapeutics, Inc. | Methods for treating cervical dystonia |
WO2022178361A1 (en) * | 2021-02-21 | 2022-08-25 | Revance Therapeutics, Inc. | Methods of and compositions for treatment of upper limb spasticity |
CN113432267A (zh) * | 2021-06-29 | 2021-09-24 | 哈尔滨蛐宝科技有限公司 | 一种基于wifi的空气消毒智能控制方法和装置 |
WO2023019206A1 (en) * | 2021-08-12 | 2023-02-16 | AEON Biopharma, Inc. | Single-use neurotoxin formulations and packaging |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008531732A (ja) * | 2005-03-03 | 2008-08-14 | ルバンス セラピュティックス インク. | ボツリヌス毒素の局所塗布及び経皮送達のための組成物及び方法 |
WO2007059528A2 (en) * | 2005-11-17 | 2007-05-24 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins |
PL2379104T3 (pl) * | 2008-12-31 | 2018-07-31 | Revance Therapeutics, Inc. | Preparaty toksyny botulinowej do wstrzykiwania |
US20140242110A1 (en) * | 2013-02-28 | 2014-08-28 | Dt Scimed, Llc | Dose, localization, and formulation of botulinum toxins in skin and muscle |
US9480731B2 (en) * | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
WO2016092365A1 (en) * | 2014-12-08 | 2016-06-16 | JJSK R&D Pte Ltd | Carrier molecule compositions and related methods |
CN109069608A (zh) * | 2015-10-29 | 2018-12-21 | 雷文斯治疗公司 | 具有长的治疗或美容效应持续时间的可注射肉毒杆菌毒素制剂以及其使用方法 |
-
2018
- 2018-12-04 KR KR1020207018682A patent/KR20200105829A/ko active Search and Examination
- 2018-12-04 CA CA3084175A patent/CA3084175A1/en active Pending
- 2018-12-04 RU RU2020121540A patent/RU2020121540A/ru unknown
- 2018-12-04 EP EP18885773.4A patent/EP3720475A4/en active Pending
- 2018-12-04 CN CN201880088069.0A patent/CN111655279A/zh active Pending
- 2018-12-04 AU AU2018378465A patent/AU2018378465A1/en active Pending
- 2018-12-04 JP JP2020530517A patent/JP2021505570A/ja active Pending
- 2018-12-04 WO PCT/US2018/063942 patent/WO2019113133A1/en unknown
- 2018-12-04 US US16/770,033 patent/US20200384090A1/en not_active Abandoned
- 2018-12-04 MX MX2020005785A patent/MX2020005785A/es unknown
- 2018-12-04 SG SG11202005239YA patent/SG11202005239YA/en unknown
- 2018-12-04 BR BR112020011098-1A patent/BR112020011098A2/pt not_active Application Discontinuation
-
2020
- 2020-06-01 IL IL275032A patent/IL275032A/en unknown
- 2020-06-04 PH PH12020550821A patent/PH12020550821A1/en unknown
- 2020-07-02 CO CONC2020/0008231A patent/CO2020008231A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
PH12020550821A1 (en) | 2021-05-10 |
BR112020011098A2 (pt) | 2020-11-17 |
CN111655279A (zh) | 2020-09-11 |
KR20200105829A (ko) | 2020-09-09 |
AU2018378465A1 (en) | 2020-07-09 |
RU2020121540A (ru) | 2022-01-10 |
JP2021505570A (ja) | 2021-02-18 |
CA3084175A1 (en) | 2019-06-13 |
IL275032A (en) | 2020-07-30 |
WO2019113133A1 (en) | 2019-06-13 |
US20200384090A1 (en) | 2020-12-10 |
CO2020008231A2 (es) | 2020-08-10 |
RU2020121540A3 (es) | 2022-04-27 |
SG11202005239YA (en) | 2020-07-29 |
EP3720475A1 (en) | 2020-10-14 |
EP3720475A4 (en) | 2021-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018005256A (es) | Formulaciones inyectables de toxina botulinica y metodos de uso de las mismas que tienen efecto terapautico o cosmetico de larga duracion. | |
PH12020550821A1 (en) | Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration | |
AU2018253620A1 (en) | Injectable botulinum toxin formulations | |
MX2020001513A (es) | Agentes de union a clec9a y su uso. | |
MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
JOP20190146A1 (ar) | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد | |
MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
TR201900649T4 (tr) | Oküler hastalıkların tedavisi için mrna tedavisi. | |
PH12018502634A1 (en) | Topical compositions of apremilast | |
WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
MX2020010907A (es) | Mejora de suministro de agentes activos lipofilicos a traves de la barrera hematoencefalica y metodos para tratar trastornos del sistema nervioso central. | |
WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
MX2023007212A (es) | Formulaciones de pulverizacion de epinefrina. | |
MX2022010186A (es) | Neurotoxinas botulinas para uso en terapia. | |
MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
FR3034993B1 (fr) | Conditionnement unitaire, compositions et schemas therapeutiques pour l'administration de stimulateurs des voies de pro-resolution sur des surfaces keratiniques | |
MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
WO2018143552A3 (ko) | 탈모방지 또는 발모촉진용 주사용 조성물 | |
MX2020008208A (es) | Agentes de unión a fibroblastos y uso de estos. | |
NZ759173A (en) | Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments | |
WO2018025080A3 (en) | Compositions for enhancing brain activity | |
NZ766141A (en) | Isoxazoline parasiticide formulations and methods for treating blepharitis | |
MY194448A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
WO2019043176A3 (en) | HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY |